Sugi Predict

Sugi Predict / Compounds / SCHEMBL31040764

SCHEMBL31040764

SCHEMBL31040764

C=C1COC(C)c2cc(C(F)(F)F)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 1/20 0.40
▸ HTR2A P28223 3/20 0.38
▸ HTR2C P28335 3/20 0.38
▸ HTR2B P41595 3/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CHRNB2 P17787 2/20 0.36
▸ CHRNA4 P43681 2/20 0.36
▸ CHRNB4 P30926 1/20 0.36
▸ CHRNA3 P32297 1/20 0.36
▸ TERT O14746 1/20 0.34
▸ KIF11 P52732 1/20 0.33
▸ CYP11B1 P15538 2/20 0.33
▸ CYP11B2 P19099 2/20 0.33
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ TDP2 O95551 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31064308 1.00 PNMT (0.40) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL31040710 0.82 CA1 (0.40) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL31064355 0.82 CA1 (0.40) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL31064242 0.81 PNMT (0.37) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL31064748 0.78 HTR2A (0.36) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL31064577 0.76 METAP1 (0.37) HTR2AHTR2CHTR2BCA1CA2
SCHEMBL31040873 0.73 TERT (0.39) PNMTHTR2AHTR2CHTR2BCA1
SCHEMBL26918434 0.68 TDP2 (0.41) PNMTHTR2AHTR2CHTR2BTDP2
SCHEMBL31544263 0.68 TDP2 (0.41) PNMTHTR2AHTR2CHTR2BTDP2
SCHEMBL31137113 0.68 CHRNB2 (0.41) PNMTHTR2AHTR2CHTR2BCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070134-A Use of PRMT5 inhibitors in the treatment of tumors or cancers 上海湃隆生物科技有限公司 2026-05-19 — — CN disclosed
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-07 — — US disclosed
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 — — EP disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 — — US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 — — US disclosed
EP-4592289-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-07-30 — — EP disclosed
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2025-02-13 — — US disclosed
US-12173002-B2 PRMT5 inhibitors and methods of use SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-12-24 — — US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 — — US disclosed
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 — — US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 — — WO disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 — — WO disclosed
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 PNMT 815/4885HTR2A 4304/4885HTR2C 4179/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 PNMT 217/4885HTR2A 4425/4885HTR2C 4597/4885
US-12173002-B2 PRMT5 inhibitors and methods of use PRMT5, PRMT1, PRMT7 PNMT 79/4885HTR2A 4691/4885HTR2C 4544/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 PNMT 217/4885HTR2A 4425/4885HTR2C 4597/4885
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT7 PNMT 78/4885HTR2A 4850/4885HTR2C 4800/4885
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 PRMT5, PRMT6, PRMT1 PNMT 239/4885HTR2A 3519/4885HTR2C 3559/4885
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT1, PRMT5, PRMT6 PNMT 1348/4885HTR2A 4730/4885HTR2C 4307/4885
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT3 PNMT 41/4885HTR2A 4664/4885HTR2C 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.